A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL

Elizabeth Price; Andrew S. Artz; Huiman Barnhart; Shelly Sapp; Gordon Chelune; William B. Ershler; Jeremy D. Walston; Victor R. Gordeuk; Nathan A. Berger; David Reuben; Josef Prchal; Sunil V. Rao; Cindy N. Roy; Mark A. Supiano; Stanley L. Schrier; Harvey Jay Cohen

doi:10.1016/j.bcmd.2014.06.003

A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL

Elizabeth Price, Andrew S. Artz, Huiman Barnhart, Shelly Sapp, Gordon Chelune, William B. Ershler, Jeremy D. Walston, Victor R. Gordeuk, Nathan A. Berger, David Reuben, Josef Prchal, Sunil V. Rao, Cindy N. Roy, Mark A. Supiano, Stanley L. Schrier, Harvey Jay Cohen

School of Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

Original language	English (US)
Pages (from-to)	221-230
Number of pages	10
Journal	Blood Cells, Molecules, and Diseases
Volume	53
Issue number	4
DOIs	https://doi.org/10.1016/j.bcmd.2014.06.003
State	Published - Dec 1 2014

Keywords

6-Minute walk test
Hemoglobin
Intravenous iron
Unexplained anemia

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Hematology
Cell Biology

Access to Document

10.1016/j.bcmd.2014.06.003

Cite this

Price, E., Artz, A. S., Barnhart, H., Sapp, S., Chelune, G., Ershler, W. B., Walston, J. D., Gordeuk, V. R., Berger, N. A., Reuben, D., Prchal, J., Rao, S. V., Roy, C. N., Supiano, M. A., Schrier, S. L., & Cohen, H. J. (2014). A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL. Blood Cells, Molecules, and Diseases, 53(4), 221-230. https://doi.org/10.1016/j.bcmd.2014.06.003

Price, E, Artz, AS, Barnhart, H, Sapp, S, Chelune, G, Ershler, WB, Walston, JD, Gordeuk, VR, Berger, NA, Reuben, D, Prchal, J, Rao, SV, Roy, CN, Supiano, MA, Schrier, SL & Cohen, HJ 2014, 'A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL', Blood Cells, Molecules, and Diseases, vol. 53, no. 4, pp. 221-230. https://doi.org/10.1016/j.bcmd.2014.06.003

@article{f2360f2f1cba45e28b7ae83d155300ed,

title = "A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL",

abstract = "Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.",

keywords = "6-Minute walk test, Hemoglobin, Intravenous iron, Unexplained anemia",

author = "Elizabeth Price and Artz, {Andrew S.} and Huiman Barnhart and Shelly Sapp and Gordon Chelune and Ershler, {William B.} and Walston, {Jeremy D.} and Gordeuk, {Victor R.} and Berger, {Nathan A.} and David Reuben and Josef Prchal and Rao, {Sunil V.} and Roy, {Cindy N.} and Supiano, {Mark A.} and Schrier, {Stanley L.} and Cohen, {Harvey Jay}",

note = "Publisher Copyright: {\textcopyright} 2014.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.bcmd.2014.06.003",

language = "English (US)",

volume = "53",

pages = "221--230",

journal = "Blood Cells, Molecules, and Diseases",

issn = "1079-9796",

publisher = "Academic Press Inc.",

number = "4",

}

TY - JOUR

T1 - A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL

AU - Price, Elizabeth

AU - Artz, Andrew S.

AU - Barnhart, Huiman

AU - Sapp, Shelly

AU - Chelune, Gordon

AU - Ershler, William B.

AU - Walston, Jeremy D.

AU - Gordeuk, Victor R.

AU - Berger, Nathan A.

AU - Reuben, David

AU - Prchal, Josef

AU - Rao, Sunil V.

AU - Roy, Cindy N.

AU - Supiano, Mark A.

AU - Schrier, Stanley L.

AU - Cohen, Harvey Jay

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

AB - Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

KW - 6-Minute walk test

KW - Hemoglobin

KW - Intravenous iron

KW - Unexplained anemia

UR - http://www.scopus.com/inward/record.url?scp=84908087455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908087455&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2014.06.003

DO - 10.1016/j.bcmd.2014.06.003

M3 - Article

C2 - 25065855

AN - SCOPUS:84908087455

SN - 1079-9796

VL - 53

SP - 221

EP - 230

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

IS - 4

ER -

A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this